Xxdusxxharxxceuxxcalxxusaxxnc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxdusxxharxxceuxxcalxxusaxxnc Pharmaceutical Import Records from India — 3 Products, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxdusxxharxxceuxxcalxxusaxxnc — Pharmaceutical Importer Profile (2026) | 3 Products, $1.2M Trade | TransData Nexus

Xxdusxxharxxceuxxcalxxusaxxnc

Pharmaceutical Importer · United States · Antibiotics Focus · $1.2M Total Trade · DGFT Verified

Xxdusxxharxxceuxxcalxxusaxxnc is a pharmaceutical importer based in United States with a total trade value of $1.2M across 3 products in 3 therapeutic categories. Based on 24 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxdusxxharxxceuxxcalxxusaxxnc sources from 2 verified Indian suppliers, with Zydus Lifesciences Limited accounting for 99.5% of imports.

Xxdusxxharxxceuxxcalxxusaxxnc — Import Portfolio & Supplier Network

Xxdusxxharxxceuxxcalxxusaxxnc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxdusxxharxxceuxxcalxxusaxxnc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Lifesciences Limited	$6.1M	136	99.5%
Cadila Healthcare Limited	$31.0K	1	0.5%

Xxdusxxharxxceuxxcalxxusaxxnc sources from 2 verified Indian suppliers across .

What Formulations Does Xxdusxxharxxceuxxcalxxusaxxnc Import?

Formulation	Value	Ships
Metoprolol succinate er TAB 50 MG	$708.0K	15
Atorvastatin calcium tablets USP 40 MG	$366.7K	8
Atorvastatin calcium tablets USP 80 MG	$314.5K	7
Exemestane tablets 25 MG - 1 x 30.	$300.0K	6
Trazodone hcl tablets USP 100 MG	$261.9K	6
Amitriptyline hcl TAB USP 10 MG	$218.4K	6
Famotidine tablets USP 40 MG - 1 x 1000.	$200.0K	4
Methotrexate tablets USP 2.5 MG 100's	$200.0K	4
Colestipol hydrochloride tablets	$150.0K	3
Budesonide enteric coated capsule 3 MG	$150.0K	3
Colestipol hydrochloride tablets USP	$150.0K	3
Doxycycline capsules USP 100 MG 50's	$150.0K	3
Methotrexate tablets USP 2.5 MG	$137.8K	3
Trazodone hcl tablets USP 150 MG	$137.6K	3
Metoprolol succinate er TAB 25 MG	$121.9K	3

Xxdusxxharxxceuxxcalxxusaxxnc imports 66 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Doxycycline	Antibiotics	$500.0K	10	0.4%	16
2	Methotrexate	Immunosuppressants	$400.0K	8	1.1%	6
3	Exemestane	Advanced Oncology	$300.0K	6	2.1%	6

Xxdusxxharxxceuxxcalxxusaxxnc imports 3 pharmaceutical products across 3 categories into United States totaling $1.2M.

Xxdusxxharxxceuxxcalxxusaxxnc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxdusxxharxxceuxxcalxxusaxxnc is a United States-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a buyer within the U.S. pharmaceutical distribution network, focusing on sourcing and importing a diverse range of pharmaceutical products to meet domestic market demands. While specific details about its headquarters and parent company are not publicly disclosed, Xxdusxxharxxceuxxcalxxusaxxnc plays a significant role in facilitating the availability of imported pharmaceutical products in the U.S. market.

2Distribution Network

The distribution network of Xxdusxxharxxceuxxcalxxusaxxnc encompasses a range of logistics capabilities designed to ensure efficient delivery of pharmaceutical products across the United States. While specific warehouse locations and geographic coverage details are not publicly available, the company's operations likely involve partnerships with third-party logistics providers and distribution centers strategically located to serve various regions within the U.S. This network enables Xxdusxxharxxceuxxcalxxusaxxnc to effectively manage the importation and distribution of pharmaceutical formulations sourced from India.

3Industry Role

In the U.S. pharmaceutical supply chain, Xxdusxxharxxceuxxcalxxusaxxnc functions primarily as an importer and distributor of finished pharmaceutical formulations. By sourcing products from Indian manufacturers, the company contributes to the diversification of the U.S. pharmaceutical market, offering a broader range of medications to meet patient needs. Its role is crucial in ensuring the availability of imported pharmaceutical products, thereby enhancing competition and potentially leading to more affordable options for healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxdusxxharxxceuxxcalxxusaxxnc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxdusxxharxxceuxxcalxxusaxxnc's sourcing strategy exhibits a high degree of concentration, with 99.5% of its imports originating from Zydus Lifesciences Limited, a prominent Indian pharmaceutical manufacturer. This significant reliance on a single supplier indicates a strategic choice aimed at leveraging Zydus's extensive product portfolio and established reputation. However, such concentration also introduces potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges within Zydus. The company's limited engagement with other suppliers suggests a need for diversification to mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

The resilience of Xxdusxxharxxceuxxcalxxusaxxnc's supply chain is closely tied to the stability and reliability of Zydus Lifesciences Limited. Given the heavy reliance on a single supplier, the company may face challenges in maintaining a consistent supply of pharmaceutical products in the event of disruptions affecting Zydus. The limited number of unique suppliers and formulations imported further underscores the need for Xxdusxxharxxceuxxcalxxusaxxnc to explore alternative sourcing options and diversify its supplier base to enhance supply chain robustness.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations that ensure the safety, efficacy, and quality of drugs entering the U.S. market. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which provides the legal framework for drug approval and regulation. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent, necessitating that foreign manufacturers obtain FDA approval for each product intended for import. Good Manufacturing Practice (GMP) certification is a critical component of this approval process, ensuring that manufacturing facilities adhere to standards that guarantee product quality and safety. The FDA recognizes GMP certifications from various international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the acceptance of foreign-produced pharmaceuticals in the U.S. market.

Xxdusxxharxxceuxxcalxxusaxxnc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxdusxxharxxceuxxcalxxusaxxnc's focus on importing antibiotics, immunosuppressants, and advanced oncology drugs aligns with significant therapeutic needs in the U.S. market. The substantial import values in these categories indicate a strategic emphasis on addressing prevalent health conditions such as infections, autoimmune disorders, and various cancers. Market demand for these products is driven by factors including the prevalence of chronic diseases, an aging population, and the ongoing need for effective treatments in these therapeutic areas.

2Sourcing Profile

Xxdusxxharxxceuxxcalxxusaxxnc's sourcing strategy is centered on procuring generic drugs from India, leveraging the country's robust pharmaceutical manufacturing capabilities. The company's preference for finished pharmaceutical formulations over active pharmaceutical ingredients (APIs) suggests a focus on ready-to-market products that can be swiftly integrated into the U.S. supply chain. India's established reputation for producing high-quality generics at competitive prices makes it a strategic partner for Xxdusxxharxxceuxxcalxxusaxxnc's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Xxdusxxharxxceuxxcalxxusaxxnc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Xxdusxxharxxceuxxcalxxusaxxnc, particularly in therapeutic areas where the company seeks to expand its product offerings. Gaps in the current sourcing strategy, such as the limited number of unique suppliers and formulations, present avenues for Indian exporters to introduce complementary products or alternative formulations that align with Xxdusxxharxxceuxxcalxxusaxxnc's existing portfolio. Establishing partnerships with Xxdusxxharxxceuxxcalxxusaxxnc could facilitate entry into the U.S. market and enhance the diversity of available pharmaceutical products.

2Requirements & Qualifications

Indian exporters aiming to supply Xxdusxxharxxceuxxcalxxusaxxnc and the broader U.S. market must ensure that their products are FDA-approved, demonstrating bioequivalence to the reference listed drug. Manufacturing facilities should hold GMP certifications recognized by the FDA, such as those from WHO or PIC/S. Additionally, compliance with U.S. labeling requirements, including English language labeling and adherence to serialization mandates, is essential. Exporters must also be prepared to navigate the FDA's regulatory processes, including ANDA submissions and facility inspections.

How to Approach

Frequently Asked Questions — Xxdusxxharxxceuxxcalxxusaxxnc

What products does Xxdusxxharxxceuxxcalxxusaxxnc import from India?

Xxdusxxharxxceuxxcalxxusaxxnc imports 3 pharmaceutical products across 3 categories. Top imports: Doxycycline ($500.0K), Methotrexate ($400.0K), Exemestane ($300.0K).

Who supplies pharmaceuticals to Xxdusxxharxxceuxxcalxxusaxxnc from India?

Xxdusxxharxxceuxxcalxxusaxxnc sources from 2 verified Indian suppliers. The primary supplier is Zydus Lifesciences Limited (99.5% of imports, $6.1M).

What is Xxdusxxharxxceuxxcalxxusaxxnc's total pharmaceutical import value?

Xxdusxxharxxceuxxcalxxusaxxnc's total pharmaceutical import value from India is $1.2M, based on 24 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxdusxxharxxceuxxcalxxusaxxnc focus on?

Xxdusxxharxxceuxxcalxxusaxxnc imports across 3 categories. The largest: Antibiotics (41.7%), Immunosuppressants (33.3%), Advanced Oncology (25.0%).

Get Full Xxdusxxharxxceuxxcalxxusaxxnc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.